Pan Cancer T

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

http://www.pancancer-t.com

2-10 employees

Growth Trajectory

The company plans to expand its pipeline of TCR therapeutics targeting 10 major solid tumors, focusing on augmenting T cells for deeper and more durable responses. They are investing in building capabilities from research to clinic and exploring gene-engineering of T cells to advance adoptive T cell therapy. Partnerships with organizations like Erasmus MC and NecstGen BV, along with funding, support their advancements in T cell therapies.

Technical Challenges

Overcoming tumor suppression

Identifying and validating novel tumor-specific targets

Engineering T cells for enhanced durability and deeper responses

Scaling T cell manufacturing for clinical trials and commercialization

Integrating retroviral vector development

Tech Stack

TCR-T cell therapyGene-engineering of T cells

Team Size

Supervisory Board

Research and Development Team

Clinical Development Team

Manufacturing Team

Key Risks

Tumors sustaining a hostile environment could limit the effectiveness of the therapies.

The need for more solid tumor-specific targets to broaden the scope of eligible cancer types and patient populations poses a challenge.

Scaling large-scale T cell manufacturing might present difficulties.

Integration complexities with retroviral vector development could arise during the therapeutic development process.

Competition in the immunotherapy space may impact market share and adoption.

Opportunities

Leveraging their discovery engine for novel tumor targets and highly specific TCRs.

Capitalizing on untapped and unique tumor-restricted targets across 10 solid cancers.

Further improving T cell therapies to progress them clinically.

Expanding through partnerships with research institutions, manufacturing facilities, and funding partners.

Developing tailored treatments for cancer patients through adoptive cellular therapy.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes